Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Silence TherapeuticsSLN -0.37%36 10-Year Share Buyback Ratio is -9.00 as of Jun. 2026. GuruFocus rates SLN with a GF Score™ of 36/100 and a GF Value™ of $0.10 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 667 Biotechnology companies, Silence Therapeutics ranks better than 56.37% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Silence Therapeutics's current 10-Year Share Buyback Ratio was -9.00%.
SLN's 10-Year Share Buyback Ratio is ranked better than 56.37% of 667
companies
in the Biotechnology industry
Industry Median: -11.7
vs SLN: -9.00
Silence Therapeutics (NAS:SLN) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Silence Therapeutics 10-Year Share Buyback Ratio Related Terms
SLN vs NAUT, CHRS, NBP: 10-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Silence Therapeutics's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics 10-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's 10-Year Share Buyback Ratio falls into.
Silence Therapeutics 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -9.00 mean?
Silence Therapeutics (SLN) has a 10-Year Share Buyback Ratio of -9.00 as of Jun. 2026. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Silence Therapeutics and its competitors. According to the industry distribution chart, Silence Therapeutics ranks #291 out of 667 companies in the Biotechnology industry, placing it in the top 43.6%.
Is Silence Therapeutics' 10-Year Share Buyback Ratio too high?
Silence Therapeutics' current 10-Year Share Buyback Ratio is -9.00. Based on the distribution chart, Silence Therapeutics ranks #291 out of 667 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Silence Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' 10-Year Share Buyback Ratio compare to NAUT and CHRS?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #291 out of 667 companies for 10-Year Share Buyback Ratio. This puts Silence Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Biotechnology company?
A good 10-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Silence Therapeutics and its competitors. Silence Therapeutics's current 10-Year Share Buyback Ratio is -9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.10, compared to a current price of $13.42 — trading 13320% above its estimated fair value. The current 10-Year Share Buyback Ratio is -9.00. Silence Therapeutics' overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current 10-Year Share Buyback Ratio is -9.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $13.42 is trading 13320% above its estimated GF Value™ of $0.10.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
10-Year Share Buyback Ratio: -9.00
GF Value™: $0.10 vs. price of $13.42 (13320% above fair value)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
36GF Score
Get the complete analysis for SLN
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
